Lymph node dissection for upper tract urothelial carcinoma: A systematic review

Vinson Wai‐Shun Chan, Chris Ho Ming Wong, Yuhong Yuan, Jeremy Yuen‐Chun TeohArab 2020 · DOI

TL;DR

This systematic review investigated whether lymph node dissection (LND) during nephroureterectomy (NU) for upper tract urothelial carcinoma (UTUC) improves patient survival. The study found no overall survival benefit from LND, but it may offer a potential benefit for recurrence-free survival in patients with muscle-invasive or advanced UTUC, without increasing complication risks.

What Problem Does This Paper Address?

Upper tract urothelial carcinoma (UTUC) is a relatively rare form of bladder cancer, accounting for only 5-10% of all urothelial carcinomas. It's often diagnosed late, with over half of cases being muscle-invasive at presentation, leading to a poorer prognosis than lower tract urothelial carcinoma. Radical nephroureterectomy (NU) is the standard treatment for non-metastatic UTUC. A key question in its management is the role and benefit of lymph node dissection (LND) during this procedure. While LND is performed for staging and potentially to remove microscopic disease, its impact on survival outcomes and complication rates in UTUC patients has been unclear, leading to variations in clinical practice. This paper aims to systematically review the existing evidence to clarify these benefits.

Methods

The authors conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. They performed a comprehensive literature search across multiple databases (MEDLINE, EMBASE, CENTRAL, Cochrane Database of Systematic Reviews) using keywords related to UTUC and LND. Studies were screened independently by two reviewers, with a third reviewer resolving any conflicts. The inclusion criteria focused on cohort studies comparing radical NU with or without LND.

For data synthesis, meta-analyses were performed where outcomes were reported consistently across studies. The Mantel-Haenszel method and random effects models were used for dichotomous data and time-to-event data (hazard ratios for survival), respectively. Risk ratios (RR) and hazard ratios (HR) were reported with 95% confidence intervals (CI). Heterogeneity between studies was assessed using I² and chi-square statistics. Qualitative data were presented narratively. The risk of bias (RoB) in the included studies was assessed using a modified Cochrane Risk of Bias Assessment tool.

Datasets

Not discussed in the paper. The paper is a systematic review of existing literature, not an empirical study using specific datasets.

Key Insights and Ideas

  • No Universal Survival Benefit: The most striking finding is that, overall, performing LND during NU for UTUC does not appear to significantly improve cancer-specific survival (CSS) or overall survival (OS). This challenges the routine application of LND in all UTUC cases.
  • Potential Benefit in Advanced Disease: A nuanced insight is the potential benefit of LND for recurrence-free survival (RFS) specifically in patients with muscle-invasive (pT2) and advanced (pT3) UTUC. This suggests that LND might be more crucial for patients with higher-risk disease.
  • Importance of Lymph Node Yield: Some studies suggest that removing a higher number of lymph nodes (e.g., eight or more) may be associated with better prognostic benefits, particularly in pN0 patients. This highlights that how much LND is performed might be as important as whether it's performed.
  • Lack of Standardized Templates: A significant limitation identified is the considerable variation in LND templates and surgical approaches across studies. This lack of standardization makes it difficult to reliably interpret results and compare outcomes.
  • No Increased Complication Risk: Importantly, the review found no significant increase in postoperative complications associated with performing LND compared to not performing it. This is a crucial piece of information for surgical decision-making.

Key Results

  • Recurrence Rate: Meta-analysis of three studies (577 patients) showed no significant reduction in recurrence rate at ≥36 months with LND (RR 1.14, 95% CI 0.83–1.57).
  • Recurrence-Free Survival (RFS):
    • When comparing LND vs. non-LND groups across four studies, no significant difference in RFS was detected (HR 0.89, 95% CI 0.41–1.92).
  • However, in a subgroup analysis of two studies focusing on muscle-invasive (pT2) and advanced (pT3) UTUC, not performing LND significantly increased the risk of recurrence (HR 2.83, 95% CI 1.72–4.66).
  • Cancer-Specific Survival (CSS): Meta-analysis of four studies showed no significant difference in CSS (HR 0.89, 95% CI 0.54–1.46). Some individual studies suggested benefits in advanced disease.
  • Overall Survival (OS): Meta-analysis of four studies found no significant difference in OS (HR 1.10, 95% CI 0.93–1.30).
  • Postoperative Complications: Five studies involving 18,584 patients found that LND was not associated with higher rates of postoperative complications (RR 1.06, 95% CI 1.00–1.13).

Limitations and Future Work

The authors acknowledge several limitations:

  • Lack of High-Quality Evidence: The review included no randomized controlled trials (RCTs), and the quality of the included studies was generally low, as reflected by the risk of bias assessment. This is attributed to the rarity of UTUC.
  • Lack of Standardization: Significant variations existed in LND templates, surgical approaches, and the use of chemotherapy across studies, which could affect the reliability and interpretation of the findings.
  • Geographic Bias: Most included studies were conducted in East Asia, potentially limiting the generalizability of findings to other populations.

The authors strongly advocate for a large-scale, prospective, multicenter randomized controlled trial to definitively investigate the role of LND in UTUC. Future research should also focus on stratifying patients by tumor laterality, location, and disease status to better understand the treatment effects of LND. The potential impact of standardized LND protocols on cancer control, especially in node-positive disease, remains an interesting area for future investigation.

Summary updated

Abstract

Overall, LND did not provide additional benefit in RFS, CSS and OS. However, there was a potential benefit in RFS in patients with muscle-invasive and advanced UTUC. LND was also not associated with increased risks of postoperative complications.<b>Abbreviations:</b> CIS: carcinoma <i>in situ</i>; CSS: cancer-specific survival; HR: hazard ratio; LND: lymph node dissection; NU: nephroureterectomy; OS: overall survival; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RFS: recurrence-free survival; RoB, risk of bias; RR: risk ratio; (UT)UC: (upper tract) urothelial carcinoma.
BibTeX
@inproceedings{chan2020lymph,
  author = {Vinson Wai‐Shun Chan and Chris Ho Ming Wong and Yuhong Yuan and Jeremy Yuen‐Chun Teoh},
  title = {{Lymph node dissection for upper tract urothelial carcinoma: A systematic review}},
  booktitle = {Arab},
  year = {2020},
  doi = {10.1080/2090598x.2020.1791563},
}
Figure